News 13.03.2019 Schlieren (Zurich), Switzerland, March 13, 2019 – Kuros Biosciences (SIX: KURN) today announced that its Dutch subsidiary, Kuros Biosciences BV, has received clearance for the Kuros TLIF cage from the U.S. Food and Drug Administration (FDA). The TLIF cage has been developed for the use with KUR-113, Kuros’s advanced Fibrin-PTH product candidate...
News 04.03.2019 ZURICH, Switzerland, March 04, 2019 – NovaGo Therapeutics AG, a Swiss biotech company developing human antibody therapeutics to promote regeneration after cerebral stroke, has closed a Series A financing round of CHF 10 million led by Pureos Bioventures and the strategic partner Neurimmune. Dr. Dominik Escher, Partner at Pureos Bioventures...
External events
Event date: 07.05.2019
It is the place to be for entrepreneurs, investors, researchers, analysts, political decision makers and industry stakeholders from across Europe to meet and network.
Highlights of the upcoming event 2019 on May 7, in Basel include:
650+ senior life science executives from 20+ countries attend
Presentation of the Swiss Biotech Report
Swiss Biotech Success...
Internal events
Event date: 05.03.2019
Registration
News 11.02.2019 Schlieren (Zurich), Switzerland, February 11, 2019 – Kuros Biosciences (SIX: KURN) today announced that its Dutch subsidiary, Kuros Biosciences BV, has signed a private label Original Equipment Manufacturer (OEM) agreement with SeaSpine Holdings Corporation (NASDAQ: SPNE), a global medical technology company focused on surgical solutions for the treatment of spinal...